Spectral Correlation Coefficient-based TMS

About

Brief Summary

This study will analyze the feasibility, safety, and tolerability of administering repetitive Transcranial magnetic stimulation(TMS) at frequencies other than standard 10 Hz. This study will enroll 50 subjects who will undergo one quantitative electroencephalograph, one TMS procedure to determine the appropriate frequency and intensity for treatment, weekly mood/symptom assessments, and up to 30 TMS treatments. Subjects will be asked to participate for up to 6 weeks.

Primary Purpose
Treatment
Study Type
Interventional
Phase
N/A

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
65 Years

Inclusion Criteria:

  • All subjects must be over between 18-65 years of age.
  • Must have confirmed diagnosis of severe Major Depressive Disorder (single or recurrent episode).
  • Failure to respond to a minimum of 4 trials of antidepressant medication
  • Failure to respond from at least two different agent classes
  • Accompanied by at least two evidence-based augmentation therapies (Benzodiazepines do not count).
  • Must have a trial of psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration.
  • Subjects are willing and able to adhere to the treatment schedule and required study visits

Exclusion Criteria:

  • Are mentally or legally incapacitated, unable to give informed consent
  • Have an infection or poor skin condition over the scalp where the device will be positioned
  • Have increased risk of seizure because of family history, stroke, or currently use medications that lead to increased risk for seizure
  • Diagnosis of acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform or schizoaffective disorder) in the current depressive episode.
  • Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system.
  • Presence of an implanted magnetic-sensitive medical device located less than or equal to 30 centimeters from the transcranial magnetic stimulation magnetic coil or other implanted metal items, including but not limited to a cochlear implant, implanted cardioverter defibrillator, pacemaker, vagus nerve stimulator, or metal aneurysm clips or coils, staples, or stents. (Note: Dental amalgam fillings are not affected by the magnetic field and are acceptable for use with transcranial magnetic stimulation
Share:
Study Stats
Protocol No.
19-000758
Category
Mental Health
Contact
HRAG PELTEKIAN
Location
  • UCLA Westwood
For Providers
NCT No.
NCT04040062
For detailed technical eligibility, visit ClinicalTrials.gov.